跳轉至內容
Merck
全部照片(1)

Key Documents

GE17-1440-02

Ficoll® Paque Plus

Cytiva 17-1440-02, pack of 6 × 100 mL

同義詞:

Ficoll density gradient medium, cell culture media

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352201
NACRES:
NA.25

形狀

liquid

包裝

pack of 6 × 100 mL

製造商/商標名

Cytiva 17-1440-02

顏色

Colorless to slightly yellow

pH值範圍

5.5-7.5

一般說明

Ficoll-Paque Plus is a recognized standard in laboratories worldwide for the isolation of human lymphocytes for in vitro studies.

Ficoll-Paque PLUS is a ready to use, sterile medium for isolation of lymphocytes in high yield from peripheral blood using a simple and rapid centrifugation procedure. It maintains the viability and a representative distribution of B and T lymphocytes.

應用

For in vitro isolation of lymphocytes from human peripheral blood.

特點和優勢

  • Ready to use sterile medium for isolation of human lymphocytes in high yield from peripheral blood.
  • Maintains viability and representative distribution of B and T lymphocytes.
  • Low levels of endotoxin (< 0.12 EU/mL).

儲存和穩定性

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
Store at 4 to 30 °C ()

分析報告

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

法律資訊

Ficoll is a registered trademark of Cytiva

象形圖

Flame

訊號詞

Danger

危險聲明

危險分類

Flam. Liq. 2

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 3


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Mehdi Hassanpour et al.
Stem cell research & therapy, 11(1), 139-139 (2020-03-29)
To date, many attempts are employed to increase the regenerative potential of stem cells. In this study, we evaluated the hypothesis of whether an autophagy modulation could alter differentiation potency of CD146+ cells into mature pericyte, endothelial, and cardiomyocyte lineage.
Matthew A Lakins et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(15), 4154-4167 (2020-04-30)
With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer. We have developed FS222, a bispecific tetravalent antibody targeting CD137 and PD-L1, to induce T-cell activation
Jingyong Li et al.
Arteriosclerosis, thrombosis, and vascular biology, 39(3), 446-458 (2019-01-18)
Objective- Inflammation occurs during the progression of abdominal aortic aneurysm (AAA). IL (interleukin)-33 is a pleiotropic cytokine with multiple immunomodulatory effects, yet its role in AAA remains unknown. Approach and Results- Immunoblot, immunohistochemistry, and immunofluorescent staining revealed increased IL-33 expression
Hagen Schwenzer et al.
Cell reports, 26(12), 3416-3428 (2019-03-21)
In eukaryotes, tRNAs are transcribed in the nucleus and exported to the cytosol, where they deliver amino acids to ribosomes for protein translation. This nuclear-cytoplasmic movement was believed to be unidirectional. However, active shuttling of tRNAs, named tRNA retrograde transport
Rajan George et al.
Human vaccines & immunotherapeutics, 16(4), 779-792 (2019-11-07)
Chimigen® HBV Immunotherapeutic Vaccine (C-HBV), a recombinant chimeric fusion protein comprising hepatitis B virus (HBV) S1 and S2 surface antigen fragments, Core antigen and a murine monoclonal antibody heavy chain fragment (Fc), was designed and produced in Sf9 insect cells.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務